Profile data is unavailable for this security.
About the company
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
- Revenue in EUR (TTM)428.72m
- Net income in EUR-9.11m
- Incorporated1986
- Employees1.99k
- LocationIon Beam Applications SAChemin du Cyclotron 3LOUVAIN-LA-NEUVE 1348BelgiumBEL
- Phone+32 10475811
- Fax+32 10475810
- Websitehttps://iba-worldwide.com
More ▼
Mergers & acquisitions
| Acquired company | IBAB:BRU since announced | Transaction value |
|---|---|---|
| Radcal Corp | 30.02% | -- |
Data delayed at least 15 minutes, as of Jul 23 2024 16:36 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sedana Medical AB (publ) | 14.13m | -1.96m | 225.08m | 83.00 | -- | 2.66 | 38,639.16 | 15.93 | -0.2299 | -0.2299 | 1.66 | 9.95 | 0.1564 | 1.24 | 8.10 | 2,087,443.00 | -2.17 | -5.77 | -2.28 | -6.08 | 70.50 | 64.06 | -13.85 | -36.13 | 7.38 | -- | 0.0043 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
| Detection Technology Oyj | -100.00bn | -100.00bn | 245.49m | 478.00 | -- | 3.37 | -- | -- | -- | -- | -- | 4.97 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.13 | -- | 0.081 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| Lumibird SA | 203.56m | 7.13m | 246.01m | 1.05k | 30.77 | 1.27 | 10.05 | 1.21 | 0.3559 | 0.3559 | 9.14 | 8.62 | 0.5238 | 1.09 | 4.05 | 193,497.10 | 1.83 | 3.13 | 2.44 | 3.99 | 61.68 | 61.76 | 3.50 | 5.89 | 1.62 | 2.47 | 0.4287 | 0.00 | 6.60 | 15.12 | -37.23 | -2.47 | 18.34 | -- |
| BICO Group AB | 193.56m | -137.69m | 258.00m | 837.00 | -- | 1.01 | -- | 1.33 | -22.34 | -26.39 | 31.73 | 42.97 | 0.3398 | 2.33 | 4.14 | 2,555,996.00 | -24.19 | -- | -27.59 | -- | 50.48 | -- | -71.20 | -- | 1.95 | -13.81 | 0.3933 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| Medistim ASA | 44.57m | 8.61m | 260.14m | 152.00 | 30.16 | 7.20 | 24.45 | 5.84 | 5.60 | 5.60 | 29.01 | 23.48 | 1.03 | 0.7765 | 6.15 | 3,492,704.00 | 19.95 | 22.93 | 24.07 | 28.52 | 79.02 | 78.25 | 19.31 | 20.64 | 2.99 | -- | 0.0206 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| Synektik SA | 139.39m | 17.82m | 279.08m | 164.00 | 15.66 | 7.74 | 13.99 | 2.00 | 8.94 | 8.94 | 69.92 | 18.10 | 2.12 | 14.61 | 9.11 | 3,897,992.00 | 27.09 | 10.24 | 44.28 | 15.79 | 26.38 | 22.86 | 12.78 | 8.85 | 1.17 | 13.77 | 0.1024 | 47.00 | 167.81 | -- | 409.18 | -- | -- | -- |
| Nyxoah SA | 5.13m | -43.21m | 281.76m | 147.00 | -- | 2.70 | -- | 54.94 | -1.51 | -1.51 | 0.1789 | 3.04 | 0.0389 | 0.8297 | 2.29 | 34,931.88 | -32.74 | -23.73 | -36.67 | -25.98 | 62.25 | 62.42 | -842.59 | -1,469.59 | 3.70 | -- | 0.1275 | -- | 40.99 | -- | -38.39 | -- | 100.58 | -- |
| COLTENE Holding AG | 250.50m | 12.33m | 288.00m | 1.20k | 23.33 | 2.88 | 14.85 | 1.15 | 2.00 | 2.00 | 40.62 | 16.21 | 1.33 | 1.40 | 6.58 | 201,937.60 | 6.53 | 10.48 | 10.90 | 18.74 | 64.24 | 62.68 | 4.92 | 7.47 | 0.8045 | 5.62 | 0.3172 | 79.94 | -9.13 | 3.54 | -54.05 | -6.81 | -7.72 | -7.79 |
| RaySearch Laboratories AB (publ) | 89.88m | 8.63m | 319.35m | 398.00 | 47.64 | 6.18 | 9.53 | 3.55 | 2.94 | 2.94 | 30.64 | 22.65 | 0.5313 | 5.65 | 2.97 | 2,697,136.00 | 5.10 | 1.29 | 7.80 | 1.88 | 89.92 | 90.57 | 9.60 | 2.55 | 1.19 | 47.17 | 0.4036 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| IVF Hartmann Holding AG | 152.69m | 15.63m | 329.42m | 304.00 | 21.08 | 2.11 | 15.44 | 2.16 | 6.31 | 6.31 | 61.63 | 63.07 | 0.8015 | 3.08 | 8.46 | 486,687.50 | 8.21 | 7.29 | 9.99 | 8.90 | 53.90 | 53.29 | 10.24 | 8.30 | 3.89 | -- | 0.0056 | 52.16 | -1.79 | 2.09 | 34.95 | 1.49 | -14.83 | 26.82 |
| Ion Beam Applications SA | 428.72m | -9.11m | 405.78m | 1.99k | -- | 3.68 | 168.30 | 0.9465 | -0.3139 | -0.3139 | 14.72 | 3.64 | 0.702 | 2.54 | 2.65 | 215,869.60 | -1.49 | 1.55 | -5.92 | 4.32 | 31.36 | 35.23 | -2.12 | 2.38 | 0.7103 | 1.40 | 0.2814 | 64.83 | 18.67 | 10.74 | -250.40 | -- | -8.06 | -- |
| Guerbet SA | 785.69m | 23.87m | 475.94m | 2.92k | 20.93 | 1.26 | 5.71 | 0.6058 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Stratec SE | 252.30m | 12.15m | 510.63m | 1.47k | 42.04 | 2.23 | 16.90 | 2.02 | 0.9991 | 0.9991 | 20.75 | 18.86 | 0.5906 | 1.34 | 5.11 | 165,771.40 | 2.84 | 7.07 | 3.55 | 8.20 | 25.60 | 27.32 | 4.81 | 9.70 | 0.8029 | 4.41 | 0.3826 | 40.81 | -4.63 | 6.88 | -55.29 | 3.30 | -2.16 | -7.68 |
| CellaVision AB | 60.67m | 12.10m | 512.86m | 223.00 | 42.39 | 7.89 | 32.91 | 8.45 | 5.92 | 5.92 | 29.69 | 31.81 | 0.757 | 1.68 | 8.45 | 3,106,469.00 | 15.09 | 15.30 | 17.34 | 18.24 | 67.52 | 69.03 | 19.94 | 19.98 | 2.21 | 66.29 | 0.0688 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| medmix AG | 495.06m | -1.86m | 556.99m | 2.70k | -- | 1.16 | 9.37 | 1.13 | -0.05 | -0.05 | 11.35 | 11.30 | 0.4778 | 3.40 | 5.58 | 180,474.00 | -0.0996 | 2.06 | -0.1227 | 2.49 | 32.58 | 36.38 | -0.2085 | 4.16 | 1.06 | 2.21 | 0.4361 | 67.70 | 1.99 | 1.40 | -97.41 | -64.36 | 12.01 | -- |
| Surgical Science Sweden AB | 72.13m | 17.81m | 590.11m | 265.00 | 33.12 | 1.50 | 26.01 | 8.18 | 4.08 | 4.08 | 16.51 | 89.92 | 0.1749 | 1.68 | 6.12 | 3,238,531.00 | 4.32 | 4.49 | 4.59 | 4.78 | 68.59 | 70.06 | 24.70 | 23.75 | 3.53 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Data as of Jul 23 2024. Currency figures normalised to Ion Beam Applications SA's reporting currency: Euro EUR
22.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 29 Dec 2023 | 1.86m | 6.13% |
| Belfius Insurance SA NVas of 31 Dec 2023 | 1.19m | 3.93% |
| Van Lanschot Kempen Investment Management NVas of 31 Dec 2023 | 875.39k | 2.89% |
| Paladin Asset Management Investmentaktiengesellschaft TGVas of 31 Dec 2023 | 768.77k | 2.54% |
| BNP Paribas Asset Management Belgium SAas of 30 Jun 2024 | 552.43k | 1.82% |
| NS Partners Europe SAas of 01 Feb 2024 | 430.66k | 1.42% |
| Investor Asset Management BVas of 12 Jul 2024 | 421.75k | 1.39% |
| Fidelity Management & Research Co. LLCas of 31 May 2024 | 350.60k | 1.16% |
| Norges Bank Investment Managementas of 13 Feb 2024 | 186.22k | 0.62% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 182.66k | 0.60% |
More ▼
Data from 30 Jun 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
